This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Avastin Drives Genentech

Genentech (DNA) kept climbing Tuesday, paced by a stellar second-quarter earnings report and the euphoria around its burgeoning wonder drug Avastin.

The stock, which has risen more than 50% this year alone, was recently trading at $84.75 on Instinet, up $1.25, or 1.5%, from its Monday close. The price is 75 times the 2005 earnings guidance that Genentech offered in its second-quarter release and 50 times the 2006 Thomson First Call consensus.

Genentech's second-quarter profit jumped 73% from a year ago to $296.2 million, or 27 cents a share, while earnings before special items came in at $328.6 million, or 30 cents a share. Analysts were looking for 26 cents a share on the latter basis.

Overall revenue was $1.53 billion, up from $1.13 billion a year ago and about $40 million above the Wall Street consensus. The upside was attributable to better-than-expected sales of Avastin, which did $245.7 million in revenue in the period, about $10 million better than expected.

In a late conference call Monday, the company's chief financial officer, David Ebersman, chalked up Avastin's performance to growing acceptance among colorectal specialists and increasing use outside of that diagnosis. Ebersman estimated that about 10% of Avastin patients had other diseases.

Sales of breast-cancer treatment Herceptin were $152.4 million, about $10 million better than expected, while sales of the lung-cancer drug Tarceva were $70.2 million, about $15 million ahead of forecasts. The main disappointment was Rituxan, which saw sales rise 15% from a year ago to $450.3 million, about $20 million below Wall Street estimates.

The company noted on its conference call that Herceptin benefited from increasing use in so-called adjuvant therapy for breast cancer, in which the drug is used to kill cancer cells that might have spread from the breast. The use resulted in a so-called "Dear Doctor" letter in which the company alerted doctors to the possibility of unforeseen consequences of off-label use.

The company forecast full-year EPS growth of more than 35% over 2004's 83 cents a share. That implies 2005 earnings of $1.13 a share, matching the Wall Street consensus estimate. Genentech has traditionally been conservative in its profit guidance.

"We are actively working with the Food and Drug Administration to prioritize the nine potential filings relating to our significant Phase III trial results, while we continue to develop more than 30 projects in the pipeline primarily in our oncology and immunology focus areas," Susan D. Hellmann, president of Genentech's product development, said in a statement.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $129.00 -1.10%
FB $78.97 0.00%
GOOG $558.40 0.00%
TSLA $203.34 0.00%
YHOO $44.28 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs